Logo image of GBIO

GENERATION BIO CO (GBIO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GBIO - US37148K2096 - Common Stock

5.62 USD
-0.02 (-0.35%)
Last: 1/16/2026, 8:22:16 PM
5.62 USD
0 (0%)
After Hours: 1/16/2026, 8:22:16 PM
Fundamental Rating

2

Taking everything into account, GBIO scores 2 out of 10 in our fundamental rating. GBIO was compared to 525 industry peers in the Biotechnology industry. The financial health of GBIO is average, but there are quite some concerns on its profitability. GBIO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year GBIO has reported negative net income.
  • In the past year GBIO has reported a negative cash flow from operations.
  • GBIO had negative earnings in each of the past 5 years.
  • In the past 5 years GBIO always reported negative operating cash flow.
GBIO Yearly Net Income VS EBIT VS OCF VS FCFGBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • GBIO has a Return On Assets (-51.38%) which is comparable to the rest of the industry.
  • GBIO has a Return On Equity of -123.87%. This is in the lower half of the industry: GBIO underperforms 60.57% of its industry peers.
Industry RankSector Rank
ROA -51.38%
ROE -123.87%
ROIC N/A
ROA(3y)-42.35%
ROA(5y)-35.88%
ROE(3y)-87.81%
ROE(5y)-64.94%
ROIC(3y)N/A
ROIC(5y)N/A
GBIO Yearly ROA, ROE, ROICGBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for GBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GBIO Yearly Profit, Operating, Gross MarginsGBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K

More info and screens

6

2. Health

2.1 Basic Checks

  • GBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, GBIO has more shares outstanding
  • The number of shares outstanding for GBIO has been increased compared to 5 years ago.
  • GBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GBIO Yearly Shares OutstandingGBIO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
GBIO Yearly Total Debt VS Total AssetsGBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • GBIO has an Altman-Z score of -9.83. This is a bad value and indicates that GBIO is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -9.83, GBIO is doing worse than 71.51% of the companies in the same industry.
  • GBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.83
ROIC/WACCN/A
WACC8.88%
GBIO Yearly LT Debt VS Equity VS FCFGBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 4.44 indicates that GBIO has no problem at all paying its short term obligations.
  • The Current ratio of GBIO (4.44) is comparable to the rest of the industry.
  • A Quick Ratio of 4.44 indicates that GBIO has no problem at all paying its short term obligations.
  • GBIO's Quick ratio of 4.44 is in line compared to the rest of the industry. GBIO outperforms 53.40% of its industry peers.
Industry RankSector Rank
Current Ratio 4.44
Quick Ratio 4.44
GBIO Yearly Current Assets VS Current LiabilitesGBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 57.35% over the past year.
  • The Revenue for GBIO has decreased by -17.82% in the past year. This is quite bad
EPS 1Y (TTM)57.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.35%
Revenue 1Y (TTM)-17.82%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-78.9%

3.2 Future

  • GBIO is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.09% yearly.
  • GBIO is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -26.69% yearly.
EPS Next Y33.1%
EPS Next 2Y30.28%
EPS Next 3Y17.61%
EPS Next 5Y7.09%
Revenue Next Year-39.28%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-26.69%

3.3 Evolution

GBIO Yearly Revenue VS EstimatesGBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2023 2024 2025 2028 2029 2030 2031 2032 2033 200M 400M 600M
GBIO Yearly EPS VS EstimatesGBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GBIO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GBIO Price Earnings VS Forward Price EarningsGBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GBIO Per share dataGBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15

4.3 Compensation for Growth

  • GBIO's earnings are expected to grow with 17.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.28%
EPS Next 3Y17.61%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for GBIO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

GENERATION BIO CO

NASDAQ:GBIO (1/16/2026, 8:22:16 PM)

After market: 5.62 0 (0%)

5.62

-0.02 (-0.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)03-11
Inst Owners65.38%
Inst Owner Change0%
Ins Owners2.79%
Ins Owner Change0.01%
Market Cap37.88M
Revenue(TTM)15.27M
Net Income(TTM)-62.63M
Analysts78.18
Price Target9.01 (60.32%)
Short Float %0.82%
Short Ratio0.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)33.67%
Min EPS beat(2)-7.33%
Max EPS beat(2)74.68%
EPS beat(4)2
Avg EPS beat(4)22.43%
Min EPS beat(4)-7.33%
Max EPS beat(4)74.68%
EPS beat(8)3
Avg EPS beat(8)-10.52%
EPS beat(12)6
Avg EPS beat(12)-5.45%
EPS beat(16)8
Avg EPS beat(16)-3.34%
Revenue beat(2)1
Avg Revenue beat(2)30.49%
Min Revenue beat(2)-75.81%
Max Revenue beat(2)136.78%
Revenue beat(4)3
Avg Revenue beat(4)106.66%
Min Revenue beat(4)-75.81%
Max Revenue beat(4)301.43%
Revenue beat(8)7
Avg Revenue beat(8)145.01%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-70.88%
PT rev (3m)-66.98%
EPS NQ rev (1m)-38.83%
EPS NQ rev (3m)-124.55%
EPS NY rev (1m)-17.65%
EPS NY rev (3m)-6.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-47.48%
Revenue NY rev (1m)1.2%
Revenue NY rev (3m)3.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.48
P/FCF N/A
P/OCF N/A
P/B 0.75
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-9.34
EYN/A
EPS(NY)-5.99
Fwd EYN/A
FCF(TTM)-17.02
FCFYN/A
OCF(TTM)-16.86
OCFYN/A
SpS2.27
BVpS7.5
TBVpS7.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.38%
ROE -123.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.35%
ROA(5y)-35.88%
ROE(3y)-87.81%
ROE(5y)-64.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.33%
Cap/Sales 7.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.44
Quick Ratio 4.44
Altman-Z -9.83
F-Score4
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)120.26%
Cap/Depr(5y)130.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.35%
EPS Next Y33.1%
EPS Next 2Y30.28%
EPS Next 3Y17.61%
EPS Next 5Y7.09%
Revenue 1Y (TTM)-17.82%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-78.9%
Revenue Next Year-39.28%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-26.69%
EBIT growth 1Y7.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.83%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-111.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-123.86%
OCF growth 3YN/A
OCF growth 5YN/A

GENERATION BIO CO / GBIO FAQ

Can you provide the ChartMill fundamental rating for GENERATION BIO CO?

ChartMill assigns a fundamental rating of 2 / 10 to GBIO.


Can you provide the valuation status for GENERATION BIO CO?

ChartMill assigns a valuation rating of 0 / 10 to GENERATION BIO CO (GBIO). This can be considered as Overvalued.


Can you provide the profitability details for GENERATION BIO CO?

GENERATION BIO CO (GBIO) has a profitability rating of 0 / 10.


What is the earnings growth outlook for GENERATION BIO CO?

The Earnings per Share (EPS) of GENERATION BIO CO (GBIO) is expected to grow by 33.1% in the next year.